Isogenic Cell Lines

Isogenic human disease models are a family of cells that are selected or engineered to accurately model the genetics of a specific patient population, in vitro. They are available with a genetically matched 'normal cell' to provide an isogenic system to research disease biology and novel therapeutic agents. They can be used to model any disease with a genetic foundation. Cancer is one such disease for which isogenic human disease cell line models have been widely used.1  The ONCOREF™  Isogenic engineered cell line products feature diverse oncogenic driver mutations in various pathways, including the MAPK and mTOR interactive signaling pathways. 

About the MAPK Pathaway Isogenic Cell Lines

What is an Isogenic human disease cell line model? 

Isogenic human disease models are a family of cells that are selected or engineered to accurately model the genetics of a specific patient population, in vitro. They are available with a genetically matched 'normal cell' to provide an isogenic system to research disease biology and novel therapeutic agents.[1] They can be used to model any disease with a genetic foundation. Cancer is one such disease for which isogenic human disease models have been widely used.

Click buttons bellow to download the RKO or HCT116 parental cell line (wild type) mutation summary. 

RKO Parental Cell Line Variants

 

HCT116 Parental Cell Line Variants

About the MAPK Pathway Isogenic Cell Lines for Cancer Research:

The MAPK signaling pathway encompasses a series of signal transduction events that begin with the engagement of EGFR at the outer cell membrane, and proceed through KRAS, BRAF, MEK, and ERK.  This signaling cascade ultimately results in transcriptional activation of key genes that promote cellular proliferation, survival, differentiation, motility, and angiogenesis1.  As such, the MAPK pathway is one of the most frequently activated pathways in cancer2, and several drugs have pharmacogenomics profiles that depend upon the MAPK mutational status3.  Applied StemCell has engineered a series of cell lines that feature diverse mutations in EGFR, KRAS, and BRAF.  These cell lines provide an ideal toolset for enhancing our understanding of cancer biology, or for high throughput screening to identify lead compounds for cancer therapeutics.

To learn more about our FFPE Reference Standards and other diagnostic products, WATCH our WEBINAR!

Limited Use License:

This is a limited use product. This product, any material that contains this product in whole or in part, any progeny,
modification or derivative of this product, any cell or animal made or modified by using this product, and any progeny,
modification or derivative of such cell or animal may not be transferred by the purchaser to any other person, entity or
any of the above to perform services for the benefit of any other person or entity or for commercial purpose of any
kind. This product may only be used by the purchaser for its internal research for use as a research tool for research
purposes.

FOR IN VITRO REASEARCH USE ONLY. NOT FOR THERAPEUTIC OR DIAGNOSTIC USE. BY ACCEPTING THIS PRODUCT,
RECIPIENT AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE STATEMENT.

Technical Details

Engineering Clinically Relevant Mutations - Control every aspect of your workflow

- Footprint-free mutations

- Homozygous mutations

- Paired isogenic mutation and wild-type cell lines

Point Mutation, Small Insertion, Deletion - Isogenic Cell Lines

 

Microbial Contamination Testing

The widespread contamination of cell lines with microorganisms, especially Mycoplasma. On the basis of submissions to cell banks, it is estimated that
15–35% of cell lines are contaminated with Mycoplasma. Mycoplasma infection can have marked effects on gene expression and cell behaviour and studies conducted with Mycoplasma-infected cells cannot be regarded
as valid.1 The ONCOREF

 

Point Mutation, Small Insertion, Deletion - Isogenic Cell Lines


Support Materials

ONCOREF™ Reference Standards: Application of CRISPR/Cas9 to the Generation of Isogenic Cell Lines and Reference Materials (October 2016)

Support Materials - Isogenic Cell Lines

 

 

 

 

 

 

 

 

 

 

CRISPR/Cas9 is rapidly enabling the development of new tools for enhancing our understanding oncogenic mutations in cancer. In order to aid in advancing cancer diagnosis and treatment, Applied StemCell has recently engineered a series of 40 isogenic cell lines that feature diverse mutations in the MAPK pathway. These mutant lines are available as isogenic pairs for applications in lead compound discovery, or as FFPE and nucleic acid reference materials for assay development. This webinar will focus on ASC’s efforts in developing these research tools, as well as applications of the materials for the advancement of cancer research.

Highlights of this talk:

  • Overview of molecular reference materials 
  • Workflow and QC for ONCOREF™ cell line generation
  • Advantages of CRISPR-engineered molecular reference standards
  • Applications of reference materials in assay development
  • Q & A
FAQ

How are your cell lines generated?

 Applied StemCell uses CRISPR/Cas9 technology for cell line engineering.  This technology allows for footprint-free gene modification, which means that there are no selection markers or other genomic footprints that may impact your scientific results.

How do you validate mutational status in your cell lines?

All of our MAPK mutation panel cell lines are expanded from single cell clones, and the targeted mutations are validated at the genomic level by Sanger sequencing.  By generating clonal populations of mutant cell lines, we can ensure the highest quality and homogeneity of the engineered cells.

What if I need a cell line that you don’t currently offer?

In addition to providing off-the-shelf cell lines, ASC offers comprehensive cell line engineering services.  Just tell us your gene of interest and desired mutation, and we will design and engineer the cell line for you.  Talk to one of our knowledgeable sales representatives for more details.

References
  1. Akinleye, A., Furqan, M., Mukhi, N., Ravella, P. & Liu, D. MEK and the inhibitors: from bench to bedside. J. Hematol. Oncol. 6, 1–11 (2013).
  2. Santarpia, L., Lippman, S. M. & El-Naggar, A. K. Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy. Expert Opin. Ther. Targets 16, 103–119 (2012).
  3. Relling, M. V & Evans, W. E. Pharmacogenomics in the clinic. Nature 526, 343–350 (2015).
  4. Nat. Rev. Mol. Cell Biol1 (3): 233–6.
Ordering
Catalog #GENENucleotide ChangeAmino Acid ChangeMutation IDMAF%Quantity PriceQTY
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$1,250.00
$200.00

Items 1-50 of 154

Page
per page